Edison Initiates Coverage on Tissue Regenix

Edison Investment Research, a Leading International Investment Research Firm, Announces the Initiation of Full Coverage of Tissue Regenix

News provided by

Edison Investment Research

Oct 14, 2015, 06:36 ET

LONDON, October 14, 2015 /PRNewswire/ --

Highlights of the analysis by Edison's healthcare analysts Emma Ulker, Hans Bostrom and Christian Glennie are as follows:

Tissue Regenix is a UK-based company developing and commercialising medical devices for regeneration of soft tissue. It has three divisions including a US-based wound care subsidiary, orthopaedics/sports medicine and a cardiac division.

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our sum-of-the-parts DCF valuation is £325m, or 43p/share, using a 12.5% WACC. We value the wound care franchise at £175m, orthopaedics at £95m and the cardiac division at £35m. The current market capitalisation, which is subject to an estimated funding requirement of £15m needed to develop OrthoPure XT and XM in the US, does not reflect the full pipeline potential, which could ultimately be attractive to larger medtech companies. To download this report, please click here .

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Emma Ulker
Edison Investment Research
+44(0)20-3077-5738

Hans Bostrom
Edison Investment Research
+44(0)20-3681-2522

Christian Glennie
Edison Investment Research
+44(0)20-3077-5727

[email protected]

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:

LinkedIn http://www.linkedin.com/company/edison-investment-research

Twitter http://www.twitter.com/Edison_Inv_Res

YouTube http://www.youtube.com/edisonitv

SOURCE Edison Investment Research